Cargando…
Mechanisms of Acquired Resistance and Tolerance to EGFR Targeted Therapy in Non-Small Cell Lung Cancer
SIMPLE SUMMARY: Lung cancer is the major cause of cancer-related deaths worldwide. The development of targeted therapies has dramatically improved the outcome of lung cancer patients. However, despite an initial response, tumors almost invariably relapse as a result of acquired resistance. In this r...
Autores principales: | Chhouri, Houssein, Alexandre, David, Grumolato, Luca |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9856371/ https://www.ncbi.nlm.nih.gov/pubmed/36672453 http://dx.doi.org/10.3390/cancers15020504 |
Ejemplares similares
-
Tolerant/Persister Cancer Cells and the Path to Resistance to Targeted Therapy
por: Swayden, Mirna, et al.
Publicado: (2020) -
Management of acquired resistance to EGFR TKI–targeted therapy in advanced non-small cell lung cancer
por: Wu, Shang-Gin, et al.
Publicado: (2018) -
AURKB as a target in non-small cell lung cancer with acquired resistance to anti-EGFR therapy
por: Bertran-Alamillo, Jordi, et al.
Publicado: (2019) -
Targeting BRAF Activation as Acquired Resistance Mechanism to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small-Cell Lung Cancer
por: Aboubakar Nana, Frank, et al.
Publicado: (2021) -
Acquired Resistance Mechanism of EGFR Kinase Domain Duplication to EGFR TKIs in Non–Small Cell Lung Cancer
por: Lee, Chaelin, et al.
Publicado: (2022)